SENATE BILL 21-123

A BILL FOR AN ACT

CONCERNING EXPANDING THE CANADIAN PRESCRIPTION DRUG IMPORTATION PROGRAM TO INCLUDE PRESCRIPTION DRUG SUPPLIERS FROM NATIONS OTHER THAN CANADA UPON THE ENACTMENT OF LEGISLATION BY THE UNITED STATES CONGRESS AUTHORIZING SUCH PRACTICE.

Bill Summary

(Note: This summary applies to this bill as introduced and does not reflect any amendments that may be subsequently adopted. If this bill passes third reading in the house of introduction, a bill summary that applies to the reengrossed version of this bill will be available at http://leg.colorado.gov.)

In 2019, the Colorado general assembly enacted, and the governor subsequently signed into law, the Canadian prescription drug importation...
program (program) in the department of health care policy and financing (department). The bill states that the department may expand the program to allow a manufacturer, wholesale distributor, or pharmacy from a nation other than Canada to export prescription drugs into the state under the program if certain conditions are met.

If, upon the satisfaction of these conditions, the department decides to expand the program, the executive director of the department shall notify the president of the senate, the speaker of the house of representatives, and specified legislative committees, of the department's intent to do so. The executive director shall provide the notice at least 30 days before the program is expanded, and the notice may include any recommendations of the department for legislation to amend the program to reflect its expansion.

Be it enacted by the General Assembly of the State of Colorado:

1

SECTION 1. Legislative declaration. (1) The general assembly finds that:

(a) The people of the United States pay the highest prescription drug prices in the world, to the detriment of Colorado consumers, employers, and the state;

(b) The cost of prescription drugs continues to rise faster than any other major component of health care, contributing to the affordability challenge faced by Colorado consumers, employers, and the state;

(c) Given the COVID-19 pandemic and the resulting economic downturn, the affordability of prescription drugs is more important than ever in the state of Colorado;

(d) In 2019, the general assembly enacted, and the governor subsequently signed into law, Senate Bill 19-005, which created the Canadian prescription drug importation program in the department of health care policy and financing, which program requires the department, upon approval of the program by the United States secretary of health and human services, to access lower-priced prescription drugs in Canada; and
(e) Many other countries have even lower prescription drug prices than Canada, as well as different supplies of specific drugs.

(2) Therefore, the general assembly declares that by accessing additional countries' drug supplies through Colorado's drug importation program, Colorado could even further increase access and cost savings associated with the program.

SECTION 2. In Colorado Revised Statutes, add 25.5-2.5-208 as follows:

25.5-2.5-208. Expansion of program to include additional foreign suppliers - federal action required - notice to general assembly. (1) NOTWITHSTANDING ANY PROVISION OF THIS PART 2 TO THE CONTRARY, THE STATE DEPARTMENT MAY EXPAND THE PROGRAM TO ALLOW A MANUFACTURER, WHOLESALE DISTRIBUTOR, OR PHARMACY FROM A NATION OTHER THAN CANADA TO EXPORT PRESCRIPTION DRUGS INTO THE STATE UNDER THE PROGRAM IF:

(a) THE UNITED STATES CONGRESS ENACTS LEGISLATION TO AMEND 21 U.S.C. SEC. 384 OR OTHERWISE ENACTS LEGISLATION TO PERMIT STATES, INCLUDING COLORADO, TO IMPORT PRESCRIPTION DRUGS FROM FOREIGN COUNTRIES OTHER THAN CANADA;

(b) A VENDOR, IN CONSULTATION WITH THE STATE DEPARTMENT, HAS IDENTIFIED THE MANUFACTURER, WHOLESALE DISTRIBUTOR, OR PHARMACY AS A SUPPLIER THAT SATISFIES THE REQUIREMENTS OF THE PROGRAM AND THAT WILL EXPORT PRESCRIPTION DRUGS AT PRICES THAT WILL PROVIDE COST SAVINGS TO THE STATE;

(c) THE MANUFACTURER, WHOLESALE DISTRIBUTOR, OR PHARMACY IS APPROPRIATELY LICENSED OR PERMITTED UNDER THAT NATION'S LAWS AND REGULATIONS PERTAINING TO THE MANUFACTURING,
DISTRIBUTION, OR DISPENSING OF PRESCRIPTION DRUGS;

(d) The manufacturer, wholesale distributor, or pharmacy is located in a nation that is approved to export prescription drugs into Colorado by the United States Secretary of Health and Human Services or by another authority that is designated for such purpose by federal law; and

(e) The state department submits evidence to the president of the senate, the speaker of the house of representatives, and the health and human services committee of the senate and the health and insurance committee of the house of representatives, or any successor committees, which evidence compares the exporting nation's regulatory system for prescription drugs to the regulatory system for prescription drugs administered by the United States food and drug administration pursuant to the federal act and demonstrates that the exporting nation's regulatory system is as stringent as the system in the United States or otherwise ensures the safety, purity, and potency of the prescription drugs from the exporting nation. The evidence must compare the regulations for:

(I) Securing the supply chain for prescription drugs;

(II) Prescription drug manufacturing;

(III) Prescription drug labeling; and

(IV) Prescription drug tracking and tracing.

(2) If, upon the satisfaction of the conditions described in subsection (1) of this section, the state department decides to expand the program to allow a manufacturer, wholesale
DISTRIBUTOR, OR PHARMACY FROM A NATION OTHER THAN CANADA TO
EXPORT PRESCRIPTION DRUGS INTO THE STATE UNDER THE PROGRAM, THE
EXECUTIVE DIRECTOR SHALL NOTIFY THE PRESIDENT OF THE SENATE, THE
SPEAKER OF THE HOUSE OF REPRESENTATIVES, AND THE HEALTH AND
HUMAN SERVICES COMMITTEE OF THE SENATE AND THE HEALTH AND
INSURANCE COMMITTEE OF THE HOUSE OF REPRESENTATIVES, OR ANY
SUCCESSOR COMMITTEES, OF THE STATE DEPARTMENT'S INTENT TO DO SO.
THE EXECUTIVE DIRECTOR SHALL PROVIDE THE NOTICE AT LEAST THIRTY
days before the program is expanded, and the notice may include
any recommendations of the state department for legislation to
amend this part 2 to reflect the expansion of the program.

(3) IF THE STATE DEPARTMENT EXPANDS THE PROGRAM IN
ACCORDANCE WITH THIS SECTION, AN ELIGIBLE IMPORTER MAY IMPORT A
PRESCRIPTION DRUG FROM A FOREIGN SUPPLIER PURSUANT TO THIS
SECTION IF THE DRUG THAT IS TO BE IMPORTED IS A PRESCRIPTION DRUG,

SECTION 3. Act subject to petition - effective date. This act
takes effect at 12:01 a.m. on the day following the expiration of the
ninety-day period after final adjournment of the general assembly; except
that, if a referendum petition is filed pursuant to section 1 (3) of article V
of the state constitution against this act or an item, section, or part of this
act within such period, then the act, item, section, or part will not take
effect unless approved by the people at the general election to be held in
November 2022 and, in such case, will take effect on the date of the
official declaration of the vote thereon by the governor.